2.4 Mantle Cell Lymphoma (MCL)
Most patients with MCL respond well to treatment and have an excellent prognosis. However, as with most other B-cell lymphomas, MCL patients are highly heterogeneous and have a different proportion of different genes and mutation types in the tumor. Up to 84% of the cyclin D1 (CDC10) gene rearrangement in tumors of MCL patients occurs in one or more B-cell lymphomas.